Comparison of tacrolimus levels obtained with twice-daily administration formulation (Prograf®) and with once-daily formulation (Advagraf®)
M. T. Rabuñal Ãlvarez, E. Fernández Gabriel, M. Outeda MacÃas, I. MartÃn HerranzAnn Transplant 2008; 13(1): 38-38 :: ID: 880199
Abstract
Background: To compare tacrolimus levels before and after change from conventional formulation (Prograf[sup]®)[/sup] to extend-release formulation (Advagraf[sup]®[/sup]).
Material/Methods: 100% of transplanted patients were treated with Prograf[sup]® [/sup]and change to Advagraf[sup]®[/sup] during January-May/2008. Data that was taken into account was: sex, age, type and date of transplantation (computer application Gestión Documental®), pharmacokinetic data (computer program Openlab[sup]®)[/sup]. C[sub]min[/sub] determinations by whole-blood enzyme immunoassay on IM[sub]X [/sub]analyzer (Abbott). Concentrations comparison was done by the Wilcoxon's test.
Results: There were 31patients (20 males), of an average age of 53.8±14.4 years, who were transplanted between August/1999-March/2008 (22/kidney, 6/liver, 2/lung). Before the change, Prograf[sup]®'[/sup]s average dose was 4.53±3.3 mg/day and average C[sub]min[/sub] =8.597±4.99 ng/mL. In 13 patients, with a C[sub]min-Prograf®[/sub] =7.438 ng/mL, clinicians kept the same dose when they change to new formulation, obtaining a [sub]Cmin-Advagraf®[/sub] =5.054±1.42 ng/mL; it suppose a decrease of 30,68% (p=0.001). In the rest of patients the dose does not remain during conversion: in 10 patients, with a Cmin Prograf® =6.09±2.59 ng/mL, they increased dose and a C[sub]min-Advagraf®[/sub] = 5.92±2.88 ng/mL was reached, and in 8 patients, with a C[sub]min Prograf®[/sub] =13.61±7.19 ng/mL, they diminished dose and a C[sub]min-Advagraf®[/sub] =6.56±3.47 ng/mL was obtained. C[sub]min-Advagraf®[/sub] were minor than C[sub]min-Prograf®[/sub] in all cases.
Conclusions: Clinicians do 1:1 dosage conversion, because the same behavior is expected for both formulations. They only change dose to try to modify previous concentrations. By blood levels monitoring, we observed that, in all cases, concentrations obtained with Advagraf[sup]®[/sup] were minor than with Prograf[sup]®[/sup]. This decrease, notably superior to what it is described in bibliography, presents a clinical relevancy which does necessary a confirmation by the AUC profiles comparison for both formulations.
Keywords: Barrett’s Oesophagus, Columnar mucosa, Cytocheratin 7, p53, CDX2 , Tacrolimus, Columnar mucosa
In Press
06 May 2022 : Original article
Phosphatidylethanol (PEth) for Monitoring Sobriety in Liver Transplant Candidates: Preliminary Results of D...Ann Transplant In Press; DOI: 10.12659/AOT.936293
27 Apr 2022 : Review article
A Systematic Review of the Literature on Chronic Kidney Disease Following Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.935170
Most Viewed Current Articles
31 Dec 1969 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
31 Dec 1969 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
31 Dec 1969 : Review article
Kidney Transplantation in the Times of COVID-19 – A Literature ReviewDOI :10.12659/AOT.925755
Ann Transplant 2020; 25:e925755
31 Dec 1969 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860